Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment

Luxa Biotechnology has been awarded a $4 million grant from the California Institute for Regeneration Medicine, supporting its ongoing Phase I/IIa clinical study of the RPESC-RPE-4W cell transplantation for the treatment of dry age-related macular degeneration (AMD).